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Introduction
Early treatment of patients with schizophrenia 
may be particularly important. The initial course 
of the disease is generally considered to be most 
amenable to intervention, with symptoms becom-
ing more stable after 5 years [Lieberman et  al. 
2001; McGorry et  al. 2008; Rosen and Garety, 
2005]. Indeed, when compared with patients with 
chronic disease, a higher proportion of patients 
recently diagnosed with schizophrenia were hos-
pitalized, with length of stay being longer and 
healthcare costs being higher [Nicholl et al. 2010]. 
Targeting treatments to the first 2–5 years of ill-
ness may optimize achieving desirable outcomes 
[McGorry et  al. 2008]. In addition, data from 
two observational studies reported that patients 
with recently diagnosed schizophrenia (⩽3 years) 
might be more responsive to treatment than 
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those with more long-standing disease [Dubois 
et al. 2014].
Paliperidone extended release (ER) is effective in 
the management of schizophrenia; both short-
term and long-term efficacy and safety of paliperi-
done ER have been demonstrated in randomized 
controlled trials in patients with schizophrenia. 
Paliperidone ER, an oral second-generation 
atypical antipsychotic, uses an innovative osmotic 
controlled-release oral delivery system (OROS® 
osmotic technology, Alza Pharmaceuticals, Palo 
Alto,California) in order to achieve minimal peak 
to trough fluctuations over 24 h with once-daily 
dosing, and to decrease steady-state drug concen-
trations in the body [Conley et al. 2006]. Short-
term efficacy and safety were demonstrated by 
analyzing pooled data from three 6-week rand-
omized controlled clinical trials treating patients 
with acute schizophrenia with fixed doses of 
paliperidone ER versus placebo [Davidson et  al. 
2007; Kane et  al. 2007; Marder et  al. 2007; 
Meltzer et  al. 2008]. These patients experienced 
significant improvements in psychotic symptoms, 
disease severity, and patient functioning for all 
paliperidone ER doses tested, as well as good 
safety and tolerability [Meltzer et  al. 2008]. 
Maintenance of good long-term efficacy and tol-
erability was shown using pooled data from three 
52-week, open-label, long-term extensions of ran-
domized, controlled clinical trials treating acute 
schizophrenia with paliperidone ER [Emsley et al. 
2008]. The most commonly reported treatment-
emergent adverse events (TEAEs) were insomnia 
and headache. Weight increased by a mean of 1.1 
kg at endpoint.
Studies of long-term outcomes suggest that 
patients with recently diagnosed schizophrenia 
may benefit more from treatment than patients 
with a longer duration of disease. A post hoc anal-
ysis of data from a 1-year study treating stable 
patients with risperidone long-acting injectable 
(25 mg or 50 mg every 2 weeks) compared out-
comes in a small cohort of patients with non-
acute schizophrenia diagnosed within 3 years of 
study enrolment (N = 57) versus those patients 
diagnosed for more than 3 years (N = 266) 
[Macfadden et al. 2010]. Patients more recently 
diagnosed with schizophrenia showed a trend 
toward lower relapse (10.5% versus 21.8%; p = 
0.053), and significantly better improvement in 
psychotic symptoms as assessed by Positive and 
Negative Syndrome Scale [PANSS; mean ± 
standard deviation (SD): PANSS total score 
change −10.2 ± 2.0 versus −3.8 ± 0.9; p = 0.004] 
and Clinical Global Impressions, Severity Scale 
(CGI-S; mean ± SD: CGI-S score −0.5 ± 0.1 
versus −0.2 ± 0.1; p = 0.002). Another post hoc 
analysis of data pooled from three double-blind 
trials followed by 1-year open-label extensions 
compared outcomes after switching to paliperi-
done ER in 259 patients diagnosed within 3 years 
of enrolment and 925 patients diagnosed for 
more than 3 years [Canuso et al. 2010]. Patients 
in this sample had active symptoms at enrolment 
with mean baseline PANSS total scores of around 
92–94. At endpoint from the open-label treat-
ment, patients more recently diagnosed with 
schizophrenia improved significantly by PANSS 
total score (mean ± SD: −32.3 ± 1.5 versus −26.7 
± 0.9; p = 0.001) and Personal and Social 
Performance (PSP) scale [Morosini et al. 2000] 
total score (mean ± SD: 18.8 ± 1.2 versus 14.7 ± 
0.7; p = 0.003).
Information on treatment outcomes for specific 
patient groups with paliperidone ER in the real 
world rather than clinical trial setting, however, is 
limited. A recent 6-month prospective interven-
tional study used a real-world design to explore 
the use of paliperidone ER in 1812 patients with 
nonacute schizophrenia, previously treated unsuc-
cessfully with other oral antipsychotic medications 
[Schreiner et  al. 2014]. This flexible-dose study 
supported results from previous randomized con-
trolled trials demonstrating treatment response, 
tolerability and safety of paliperidone ER under 
conditions of routine clinical practice. As recent 
research findings have suggested a higher treat-
ment response and different side-effect profile in 
patients with schizophrenia recently diagnosed 
with their disease, the current analysis explores 
6-month treatment response, safety and tolerability 
data, patient-reported outcomes, and predictors 
of response in a subset of patients from this larger 
study, specifically the subset of patients who were 
recently diagnosed with schizophrenia.
Methods
This study explored patients with non-acute schiz-
ophrenia previously unsuccessfully treated with 
another oral antipsychotic, who had been diag-
nosed with schizophrenia within 5 years. This group 
was part of a larger study (N = 1812) which has 
been published previously [Schreiner et al. 2014].
This study was conducted in Belgium, Bulgaria, 
Croatia, Denmark, Finland, France, Germany, 
Therapeutic Advances in Psychopharmacology 5(4)
196 http://tpp.sagepub.com
Greece, Hungary, Israel, Italy, Latvia, Lithuania, 
Poland, Portugal, Russia, Serbia, Spain, Sweden, 
Switzerland, Turkey, The Netherlands and the 
United Kingdom from April 2007 to January 
2009. The study was performed in accordance 
with the guidelines of the International Conference 
on Harmonization for Good Clinical Practice, and 
the study protocol was approved by Independent 
Ethics Committees. Prior to study enrolment, all 
potential participants provided written informed 
consent.
Patients
Eligible patients were inpatients or outpatients 
aged at least 18 years, with a diagnosis of schizo-
phrenia according to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition 
(DSM-IV) or a related disorder that was treated 
with an antipsychotic. All patients were diagnosed 
with a psychotic disorder within the preceding 5 
years. Schizophrenia was considered to be non-
acute when treated with an oral antipsychotic and 
the patient experienced a change in CGI-S score 
of 1 or less during the 4 weeks before enrolment. 
Patients were required to have previously received 
an adequate, that is, therapeutic dose of any other 
oral antipsychotic for a sufficient period of time 
(at least 1 month) prior to enrolment, per investi-
gator judgment. Patients were excluded if they had 
any of the following: known hypersensitivity to 
paliperidone ER or risperidone; had been treated 
with clozapine or a long-acting injectable antipsy-
chotic during the preceding 3 months; significant 
medical illness; tardive dyskinesia; neuroleptic 
malignant syndrome; high risk for adverse events 
(AEs) or self-harm; or substance dependence 
over the past 6 months (however, substance abuse 
was allowed). If patients had been treated with an 
adequate dosage of an appropriate oral antipsy-
chotic for an adequate period of time, previous 
antipsychotic treatment could be considered 
unsuccessful due to various causes, including lack 
of efficacy, tolerability or safety issues, or lack of 
compliance.
Treatment
Patients were flexibly dosed with oral paliperi-
done ER tablets (3–12 mg/day) with a recom-
mended starting dose of 6 mg once daily. Most 
patients were transitioned to an effective dose of 
paliperidone ER without titration and were 
treated for up to 6 months.
Other antipsychotics prescribed for the treatment 
of schizophrenia were not allowed during the 
entire study. Previous antipsychotics had to be 
discontinued or tapered off over a maximum of 4 
weeks based on the clinical situation and investi-
gator’s decision. Some concomitant medications 
were permitted during this study. Antipsychotics 
and other psychotropic medication administered 
prior to enrolment for conditions other than 
schizophrenia, such as sleep induction or seda-
tion, could be continued during the trial if a sta-
ble dose was maintained. Benzodiazepines were 
allowed as rescue medication during the trial for 
periods of up to 10 consecutive days. Benztropine 
mesylate or biperidene up to 4 mg/day, or trihexy-
phenidyl up to 10 mg/day were permitted for the 
treatment of extrapyramidal symptoms, with the 
need for anticholinergic medication to be evalu-
ated by the investigator on an ongoing basis.
Outcome measures
Assessments of efficacy, and safety and tolerabil-
ity were made at baseline and treatment weeks 4, 
8, 13 and 26 (or endpoint).
Efficacy assessments. The primary efficacy out-
come was based on the main reason for transi-
tioning to paliperidone ER. For patients switching 
for the main reason of lack of efficacy with a pre-
vious oral antipsychotic, the primary efficacy 
outcome was an improvement in PANSS total 
score of at least 20% [Kay et al. 1987] from base-
line to endpoint. These patients were termed 
responders. For patients switching for main rea-
sons other than lack of efficacy, the primary effi-
cacy outcome was the shift in PANSS total score 
from baseline to endpoint. Non-inferiority was 
defined as a difference of no more than 5 points 
at endpoint versus baseline on the PANSS total 
score. Schuirmann’s one-sided test was used to 
confirm non-inferiority.
The following additional efficacy measures were 
assessed at baseline and treatment week 26 (or 
endpoint): PANSS subscale and Marder factor 
[Marder et al. 1997] scores; CGI-S scores [Guy, 
1976]; and PSP scores [Morosini et  al. 2000]. 
The CGI-S scores measure symptom severity on 
a scale from 0 to 6: ‘normal’ (0); ‘borderline ill’ 
(1); ‘mildly ill’ (2); ‘moderately ill’ (3); ‘markedly 
ill’ (4); ‘severely ill’ (5); and ‘extremely ill’ (6). 
The PSP scale is a clinician-reported measure of 
severity of personal and social dysfunction which 
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was developed as an improvement upon the 
Social and Occupational Functioning Assessment 
Scale (SOFAS), and the Global Assessment of 
Functioning (GAF) scale. It is a 100-point sin-
gle-item rating scale based on the assessment of 
the functioning of patients in four distinct 
domains (socially useful activities; personal and 
social relationships; self-care; and disturbing and 
aggressive behaviours). Patient satisfaction with 
previous antipsychotic treatment at baseline and 
with paliperidone ER at endpoint was assessed 
using a 5-point scale: ‘very poor’ (5); ‘poor’ (4); 
‘moderate’ (3); ‘good’ (2); and ‘very good’ (1).
Safety and tolerability. TEAEs were recorded 
throughout the study. Extrapyramidal Symptom 
Rating Scale (ESRS) scores [Chouinard and 
Margolese, 2005] were assessed at baseline and 
treatment weeks 4, 8, 13 and 26 (or endpoint). 
Body weight was measured and body mass index 
(BMI) was calculated at baseline and at treat-
ment weeks 13 and 26 (or endpoint). Sleep quality 
and daytime drowsiness over the previous 7 days 
were scored using an 11-point ordinal scale. 
Sleep scores ranged from ‘very badly’ (0) to ‘very 
well’ (10); daytime drowsiness ranged from ‘not 
at all’ (0) to ‘all the time’ (10).
Statistical analysis
Unless stated otherwise, descriptive results of 
continuous/ordinal variables are presented as 
mean ± SD. Patients receiving at least one dose of 
paliperidone ER and having at least one post-
treatment assessment were included in the effi-
cacy and safety analyses of the intent-to-treat 
population. Patient demographics, efficacy, treat-
ment satisfaction and safety parameters were 
assessed using descriptive statistics. Primary effi-
cacy was assessed by estimating the 95% confi-
dence intervals (CIs) for treatment response. 
Within-group changes versus baseline were evalu-
ated using the two-tailed Wilcoxon signed-rank 
test (α = 0.05). For 76–80% of patients, data were 
available for baseline and week 26, and for 20–
24% the analysis reflected last observation carried 
forward (LOCF) data for endpoint only.
For the predictor analyses of treatment response, 
we used a more stringent criterion (also called 
clinical response), that is, a decrease in the PANSS 
total score from baseline to endpoint of at least 
20% and a decrease in CGI-S score of at least one 
point. For the analysis of explanatory variables for 
clinical response, a stepwise logistic regression 
was used, taking into account age, sex, BMI, diag-
nosis and duration of schizophrenia, number of 
prior hospitalizations in the previous 12 months, 
main reason for switching to paliperidone ER, 
previous antipsychotic, baseline psychotic symp-
toms assessed by PANSS score, disease severity 
assessed by CGI-S score, and functional status 
assessed by PSP score. Country of origin was 
included in all models to correct for possible non-
clinical predictors, such as clinical settings, dos-
ing, titration and concomitant medication. First, 
country and all baseline explanatory variables 
were included in the model one at a time and then 
separately; a stepwise-forward selection method 
in logistic regression analysis was used including 
all baseline explanatory variables to obtain an ini-
tial set of significant explanatory variables at the 
10% level, correcting for potential country effects. 
Second, a stepwise-forward selection method was 
used including country and the initial set of sig-
nificant explanatory variables in order to obtain a 
reduced model. Third, the nonsignificant explan-
atory variables were included in the reduced 
model (including country) and checked for sig-
nificance at the 10% level. If necessary, the sec-
ond and third steps were repeated to obtain the 
final model (including country).
Results
Patients
A total of 719 patients were screened: 3 patients 
who were screened were not enrolled into the 
study as they failed to meet the inclusion criteria, 
and 3 additional patients did not receive paliperi-
done ER (2 patients withdrew their consent after 
enrolment and 1 patient decided not to start the 
study treatment). Consequently, 713 patients were 
enrolled in the study and treated with paliperi-
done ER (Figure 1). Patients were predominantly 
male and had paranoid subtype of schizophrenia 
(Table 1). Four patients had a diagnosis other than 
schizophrenia (1 each with bipolar disorder, 
coenestopathic, pseudoneuroticism and schizo-
phrenia simplex). Although the selection criterion 
was less than 5 years since diagnosis, interestingly 
the actual mean ± SD time was only 2.3 ± 1.7 
years. The main reason for switching to paliperi-
done ER was most commonly due to lack of 
efficacy (54.3%) or tolerability issues (29.9%) 
with the previous oral antipsychotic. At baseline, 
most patients were using a single antipsychotic 
medication (83.3%), 11.5% were using more 
than one antipsychotic, and 5.2% did not use an 
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antipsychotic before baseline, which reflects a 
major protocol deviation. The most common 
previous oral antipsychotics were risperidone 
(41.1%), olanzapine (21.2%), quetiapine (10.1%), 
haloperidol (9.0%) and aripiprazole (8.8%).
For recently diagnosed patients, the mean ± SD 
initial paliperidone ER dose was 5.2 ± 1.9 mg/day 
(median: 6 mg/day), with a mean ± SD average 
dose of 6.8 ± 2.5 mg/day during the study 
(median: 6 mg/day) and mean mode ± SD dose of 
7.0 ± 2.9 mg/day (median: 6 mg/day). Mean aver-
age paliperidone ER dose for patients switching 
for reasons other than lack of efficacy was 6.2–6.3 
mg/day, which was slightly lower compared with 
patients switching for the reason of lack of effi-
cacy (average dose: 7.2 mg/day). Mean ± SD 
duration of exposure was 149.6 ± 58.7 days, with 
an increase in dosing occurring for 417 patients 
(58.5%) and a decrease for 139 patients (19.5%) 
during the study.
Efficacy
Efficacy data were available for 693 patients. For 
patients who switched due to the main reason of 
lack of efficacy (n = 377), the primary efficacy 
outcome, an improvement in PANSS total score 
of at least 20% from baseline to endpoint, 
occurred in 63.1% of patients (95% CI 58.0–
68.0). For patients switching for main reasons 
other than lack of efficacy, the primary efficacy 
outcome was non-inferiority in efficacy, defined 
as a difference of no more than 5 points in mean 
change from baseline at endpoint in PANSS total 
score. Mean ± SD baseline PANSS total scores 
were 83.6 ± 18.5 for patients switching due to 
lack of efficacy (n = 377), 66.1 ± 17.0 for patients 
switching due to lack of tolerability (n = 209), 
80.6 ± 20.8 for lack of compliance (n = 67), and 
72.7 ± 23.9 for ‘other’ reasons (n = 40). Mean ± 
SD changes from baseline to endpoint were −8.9 
± 18.2 for patients switching for the main reason 
of lack of tolerability, −18.4 ± 20.7 for lack of 
Figure 1. Patient disposition.
AE, adverse event; ER, extended release.
L Helldin, J Peuskens et al.
http://tpp.sagepub.com 199
compliance, and −11.3 ± 14.2 for ‘other’ reasons. 
Schuirmann’s one-sided test confirmed non- 
inferiority to within the specified equivalence 
bounds for each group (p < 0.0001).
Mean improvement in PANSS total scores, as 
well as PANSS subscales and Marder factors, 
from baseline to endpoint for the entire recently 
diagnosed population was statistically significant 
and clinically relevant (Table 2). For each of the 
subgroups based on main reason for switching, 
mean baseline to endpoint changes for PANSS 
total, subscale and Marder factor scores were 
significant (all p ⩽ 0.0001, except for the 
‘uncontrolled hostility/excitement’ score, which 
was p = 0.0028 for ‘other’ reason for switching 
and which was not statistically significant for 
patients switching due to lack of tolerability).
Based on CGI-S categories, 30.3% of patients 
were ‘normal’ to ‘borderline – mildly ill’ at baseline; 
this percentage increased to 56.3% at endpoint 
[Figure 2(a)]. CGI-S scores at baseline cor-
responded to ‘moderately ill’ (mean ± SD: 2.9 ± 
0.9). Baseline to endpoint improvement in CGI-S 
scores (mean ± SD: −0.6 ± 1.1) was statistically 
significant (p < 0.0001), with a CGI-S score at 
endpoint corresponding to ‘mildly ill’ (mean ± 
SD: 2.4 ± 1.2). Baseline to endpoint improve-
ment in CGI-S scores was statistically significant 
for each subgroup based on main reason for 
switching (p ⩽ 0.0001, except for ‘other’ reason 
for switching, which was p = 0.0191).
Among the 660 patients with both baseline and 
endpoint data for the PSP scale, mean ± SD 
total PSP scale score improved from 58.6 ± 
14.5 at baseline to 65.9 ± 15.7 at endpoint 
(p < 0.0001). Improvements were also statisti-
cally significant at both 13- and 26-week 
assessments (p < 0.0001). Baseline to endpoint 
improvements in PSP scale scores were statisti-
cally significant for each subgroup based on 
main reason for switching (p ⩽ 0.0001, except 
for ‘other’ reason for switching,  which was 
p = 0.0265). At baseline, only 17.7% of patients 
showed a mild degree of difficulty in function-
ing; this was increased to 39.8% at endpoint 
[Figure 2(b)]. At baseline, 5.2% of patients 
functioned so poorly that they required inten-
sive supervision; this was reduced to 3.5% at 
endpoint [Figure 2(b)].
For the total population, mean ± SD treatment sat-
isfaction scores were 3.2 ± 0.8 (representing mod-
erate satisfaction) with the prior antipsychotics at 
baseline and 2.3 ± 1.0 (representing good satisfac-
tion) with paliperidone ER at endpoint. Treatment 
satisfaction with prior antipsychotic treatment at 
baseline was rated ‘good’ to ‘very good’ by 16.8% of 
patients and at endpoint by 66.0% of patients 
treated with paliperidone ER [Figure 2(c)]. 
Proportions of patients who rated treatment satis-
faction with prior antipsychotic treatment ‘good’ to 
‘very good’ were lower for patients who switched 
due to lack of efficacy compared with patients who 
Table 1. Baseline characteristics.
Characteristic N = 713
Sex, n (%)  
  Male 434 (60.9)
  Female 279 (39.1)
Age, mean ± SD, years 33.6 ± 11.2
Time since diagnosis of 
schizophrenia, mean ± SD, years
2.3 ± 1.7
Number of previous 
hospitalizations, mean ± SD
2.3 ± 2.5
DSM-IV Axis I diagnosis, n (%)  
  Schizophrenia 709 (99.4)
  Paranoid 570 (79.9)
  Undifferentiated  88 (12.3)
  Disorganized  33 (4.6)
  Residual  17 (2.4)
  Other   5 (0.7)
Main reason for switching, n (%)  
  Lack of efficacy 387 (54.3)
  Lack of tolerability 213 (29.9)
  Lack of compliance  71 (10.0)
  Other  42 (5.9)
Baseline disease severity,  
mean score ± SD
 
  PANSS total 77.4 ± 20.2
  CGI-S 2.9 ± 0.9
  PSP 58.5 ± 14.7
Baseline CGI-S category, n (%)*  
  Normal   1 (0.1)
  Borderline – mildly ill 209 (30.2)
  Moderately ill 317 (45.7)
  Markedly – extremely ill 166 (24.0)
*N = 693 for this characteristic.
CGI-S, Clinical Global Impression, Severity; DSM-IV,  
Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition; PANSS, Positive and Negative Syndrome 
Scale; PSP, Personal and Social Performance Scale;  
SD, standard deviation.
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switched due to reasons other than lack of efficacy 
(with prior antipsychotic at baseline: 14.7% versus 
19.4%; with paliperidone ER at endpoint: 60.2% 
versus 73.1%).
Improvements in quality of sleep and daytime 
drowsiness were significant at each assessment 
and at endpoint (p < 0.0001) (Figure 3). 
Improvement in sleep quality from baseline to 
Table 2. Mean Positive and Negative Syndrome Scale (PANSS) scores at baseline and endpoint for all patients 
(N = 693).
Baseline Endpoint
PANSS total score 77.4 ± 20.2 63.7 ± 20.6***
PANSS subscale scores  
  Positive 16.6 ± 6.0 13.3 ± 5.6***
  Negative 21.7 ± 6.5 17.9 ± 6.5***
  General psychopathology 39.1 ± 10.9 32.6 ± 10.8***
Marder factors  
  Positive 20.9 ± 7.0 16.9 ± 6.9***
  Negative 21.2 ± 6.5 17.3 ± 6.4***
  Disorganized thoughts 17.3 ± 5.4 14.6 ± 5.1***
  Uncontrolled hostility/excitement 7.4 ± 3.2 6.5 ± 2.7***
  Anxiety/depression 10.5 ± 3.9 8.4 ± 3.6***
All values are mean ± standard deviation.
***p < 0.0001; change in PANSS scores (from baseline to endpoint) tested with the two-tailed Wilcoxon signed-rank test.
Figure 2. Secondary efficacy measures at baseline and endpoint: Clinical Global Impression, Severity 
categories (a); Personal and Social Performance (PSP) scale categories (b); and treatment satisfaction (c).  
ER, extended release.
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endpoint was statistically significant for patients 
switching due to lack of efficacy (p < 0.0001) and 
lack of compliance (p = 0.0003). Reduction in 
daytime drowsiness from baseline to endpoint 
was statistically significant for patients switching 
due to lack of efficacy, lack of tolerability and lack 
of compliance (p ⩽ 0.0007).
Predictor analysis
Clinical response (defined as a decrease in PANSS 
total score from baseline to endpoint of at least 
20% plus a decrease in CGI-S score of at least 
one point) occurred for 295 patients (42.6%). 
Baseline CGI-S score was a significant predictor 
of clinical response (odds ratio 1.465; 95% CI 
1.204–1.783; p < 0.001) (Table 3). There was a 
trend for the type of schizophrenia and the main 
reason for switching to paliperidone ER to also be 
predictors of clinical response (p = 0.0543 and p 
= 0.0764, respectively).
Safety and tolerability
Safety data were available for 712 treated patients, 
and 413 patients (58.0%) reported experiencing 
at least 1 TEAE (Table 4). Paliperidone ER was 
generally well tolerated. Serious TEAEs were 
experienced by 59 patients (8.3%); the most 
common serious TEAEs were psychotic disorder 
(n = 16; 2.2%), schizophrenia (n = 14; 2.0%) and 
anxiety (n = 8; 1.1%). TEAEs occurring in at least 
5% of patients were insomnia, anxiety and 
somnolence.
At baseline, a total of 33 potentially prolactin-
related AEs were reported in 30 (4.2%) patients 
with their previous oral antipsychotic: amenorrhea 
Table 3. Important clinical predictors of clinical response based on logistic regression after stepwise 
modeling.*
Variable Odds ratio 95% CI χ2 p Value
Baseline CGI-S 1.465 1.204–1.783 14.5447 <0.001
Type of diagnosis is residual or catatonic 
schizophrenia, or other type
0.329 0.106–1.021 3.7031 0.0543
Main reason for switching 6.8642 0.0764
  Lack of compliance versus lack of efficacy 1.753 0.992–3.097 3.7383 0.0532
  Lack of tolerability versus lack of efficacy 1.434 0.962–2.136 3.1302 0.0769
  Other versus lack of efficacy 0.797 0.374–1.697 0.3464 0.5562
*Country of origin was included in the model to correct for possible nonclinical predictors, like clinical settings, dosing, 
titration, and concomitant medication.
CGI-S, Clinical Global Impression, Severity; CI, confidence interval.
Figure 3. Sleep quality and daytime drowsiness.
***p < 0.0001; change from baseline to endpoint tested with the two-tailed Wilcoxon signed-rank test.
Therapeutic Advances in Psychopharmacology 5(4)
202 http://tpp.sagepub.com
(n = 13); erectile dysfunction (n = 5); sexual dys-
function (n = 5); galactorrhea (n = 3); erectile 
libido decreased/libido disorder/loss of libido/
abnormal orgasm (n = 2); ejaculation failure (n = 
2); and gynecomastia, dysmenorrhea and breast 
discharge (n = 1 each). Hyperprolactinemia or 
increased blood serum prolactin levels were 
reported in 13 (1.8%) patients at baseline.
During the study, 50 different potentially prolac-
tin-related TEAEs were reported in 45 (6.3%) 
patients: amenorrhea (n = 13); galactorrhea (n = 
13); libido disorder/decreased libido/anorgas-
mia/orgasm abnormal (n = 7); erectile dysfunc-
tion (n = 7); sexual dysfunction (n = 5); menstrual 
disorder (n = 2); and breast discharge/gyneco-
mastia/oligomenorrhea (n = 1 each). In 14 
patients (2.0%), elevated serum prolactin levels 
were reported.
Extrapyramidal symptoms, as measured by the 
ESRS, improved significantly at each assessment 
and endpoint (p < 0.0001) (Figure 4). Baseline to 
endpoint improvement in total ESRS scores was 
statistically significant for subgroups switching for 
the main reasons of lack of efficacy and lack of 
tolerability (p < 0.0001).
Baseline and endpoint body weight and BMI 
were recorded for 648 patients. For the total pop-
ulation, mean ± SD baseline weight and BMI 
were 79.4 ± 17.9 kg and 26.6 ± 5.3 kg/m2, respec-
tively. Mean ± SD weight and BMI increased, 
respectively, by: 0.7 ± 3.8 kg and 0.3 ± 1.3 kg/m2 
at week 13; 1.0 ± 5.1 kg and 0.4 ± 1.7 kg/m2 at 
week 26; and 0.9 ± 4.8 kg and 0.3 ± 1.6 kg/m2 at 
endpoint. Increases for both weight and BMI 
were statistically significant (p < 0.0001), but not 
considered clinically relevant at each assessment 
and endpoint.
Increases in body weight from baseline to end-
point were statistically significant, although not 
considered clinically relevant, for patients who 
switched from monotherapy quetiapine or risperi-
done (Figure 5). Notably, although not statisti-
cally significant, patients who switched from 
olanzapine monotherapy showed a decrease in 
body weight from baseline to endpoint.
A clinically relevant weight change (⩾7%) from 
baseline to endpoint occurred in 85 patients 
(13.1%) of the total population. In patients 
switching from haloperidol monotherapy, a clini-
cally relevant weight change was observed in 
22.6%. The proportions of patients switching 
from monotherapy with olanzapine, quetiapine or 
risperidone with relevant weight change (⩾7%) 
were 9.5%, 14.0% and 11.7%, respectively.
For the total population, statistically significant, 
although mostly not clinically relevant, body 
weight  increases were observed from baseline to 
endpoint for all patients with a baseline BMI of 
less than 25 kg/m2 (Figure 6). For patients with a 
baseline BMI of at least 30 kg/m2, no significant 
weight increases were observed.
Discussion
Paliperidone ER is an effective antipsychotic treat-
ment for patients recently diagnosed with schizo-
phrenia. A majority of patients experienced a 
clinically relevant improvement in psychotic symp-
toms. The observed improvement in symptom 
severity is in line with previous data showing that 
improvement after switching antipsychotic therapy 
may be greater among patients with greater base-
line impairment [Möller et  al. 2005]. Also, the 
Table 4. Treatment-emergent adverse events 
(TEAEs).
TEAE N = 712
⩾1 TEAE 413 (58.0)
TEAE reported as causally 
related to paliperidone ER
280 (39.3)
Serious TEAE* 59 (8.3)
Severity of TEAEs$  
  Mild 537 (48.1)
  Moderate 470 (42.1)
  Severe 109 (9.8)
TEAEs in ⩾5% of patients  
  Insomnia 76 (10.7)
  Anxiety 61 (8.6)
  Somnolence 41 (5.8)
Action taken due to TEAE$  
  None 838 (75.1)
  Dose adjustment 173 (15.5)
  Temporary discontinuation 7 (0.6)
  Permanent discontinuation 98 (8.8)
Values are presented as n (%).
*Most common were psychotic disorder (2.2%), schizo-
phrenia (2.0%) and anxiety (1.1%).
$Percentages are based on the total number of TEAEs  
(n = 1116).
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improvements in symptom severity, including pos-
itive and negative symptoms, observed here are 
consistent with data from randomized controlled 
trials [Meltzer et  al. 2008; Turkoz et  al. 2011]. 
In this context, it would be interesting to know 
whether consistent, once-daily, oral intake of 
an effective and well-tolerated antipsychotic medi-
cation can contribute to long-term efficacy and 
relapse prevention [Emsley et al. 2011]. Personal 
functioning and patient satisfaction showed 
Figure 4. Extrapyramidal symptoms as measured by mean Extrapyramidal Symptom Rating Scale (ESRS) 
total scores. Note: decreasing ESRS scores reflect improvement in extrapyramidal symptoms.
***p < 0.0001; change from baseline to endpoint tested with the two-tailed Wilcoxon signed-rank test.
Figure 5. Change in bodyweight from baseline to endpoint by previous oral antipsychotic medication.  
P Values refer to change from baseline to endpoint tested with the two-tailed Wilcoxon signed-rank test.
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improvement compared with prior antipsychotic 
treatment. This is especially important for younger 
patients because impaired personal and social 
functioning can negatively affect their education 
and social development. Furthermore, patient sat-
isfaction with treatment is an important predictor 
for adherence to antipsychotic medication [Liu-
Seifert et al. 2007].
Paliperidone ER was generally well tolerated in 
patients with recently diagnosed illness. Given 
the less sedating properties of paliperidone ER 
compared with many other second-generation 
antipsychotics, including oral risperidone [Jones 
et al. 2010; Luthringer et al. 2007; Turkoz et al. 
2011], combining paliperidone ER temporarily 
with sedating comedication and allowing for 
an adequate cross-titration when switching from 
other, in particular, sedating antipsychotics 
[Schreiner et al. 2014; Stahl, 2008] may help to 
further improve tolerability. ESRS scores showed 
statistically significant improvement after switch-
ing to paliperidone ER, which could result from 
both the pharmacokinetic and pharmacodynamic 
profile of paliperidone ER [Conley et  al. 2006; 
Ereshefsky and Mascarenas, 2003; Marchese 
et  al. 2010; Turkoz et  al. 2008]. The improve-
ments in daytime drowsiness and sleep quality 
are consistent with data from a randomized con-
trolled study comparing paliperidone ER and 
placebo [Luthringer et  al. 2007]. The clinically 
relevant (⩾7%) change in bodyweight, observed 
in our study in a minority of patients who 
switched to paliperidone ER, supports data from 
a recent post hoc analysis that shows similar long-
term tolerability with paliperidone ER among 
patients with either recently diagnosed schizo-
phrenia (⩽5 years) or with chronic illness (>5 
years) [Sliwa et al. 2012].
Efficacy outcomes in this study were similar to 
results from a post hoc assessment of a small sam-
ple of 57 patients who were diagnosed within 3 
years with schizophrenia or schizoaffective disor-
der with stable symptoms [Macfadden et  al. 
2010]. These patients were treated with risperi-
done long-acting injectable and showed greater 
improvement in mean total PANSS and CGI-S 
scores than 266 patients who had been diagnosed 
more than 3 years previously. Improvements were 
more substantial in another post hoc analysis of 
patients with active symptoms switching to pali-
peridone ER [Canuso et al. 2010]; however, base-
line impairments were also substantially greater 
in this population compared with the current 
sample with stable illness.
The results of the predictor analysis, indicating 
that patients with higher baseline disease severity 
are more likely to respond to treatment, are in line 
Figure 6. Change in bodyweight from baseline to endpoint by baseline body mass index (BMI) category.
*p < 0.05; **p < 0.001; and ***p < 0.0001; p values refer to change from baseline to endpoint tested with the two-tailed 
Wilcoxon signed-rank test.
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with other studies in patients with acute schizo-
phrenia [Heres et al. 2014] and in patients with 
first-episode schizophrenia [Crespo-Facorro et al. 
2007; Tabatabaee et al. 2008; Zhang et al. 2014]. 
These data conflict with a previously published 
analysis of drug-naive patients with schizophrenia 
in whom higher baseline CGI-S scores were a 
predictor of clinical non-response [Nordon et al. 
2014]. However, mean baseline CGI-S score in 
that study was considerably higher (4.7) than in 
the present study (2.9). A few other studies have 
also either reported higher baseline disease sever-
ity predicted clinical non-response [Perkins et al. 
2004] or no effect [Brousse et al. 2010].
The main limitations of this study are the open-
label treatment of patients with paliperidone ER, 
the absence of a comparator group and the fact 
that this is a secondary analysis. Another limitation 
is the relatively short duration of the study (up to 
6 months). Although the data do not provide 
head-to-head comparisons between treatments 
with different antipsychotics, the data do suggest 
that patients who have experienced failure in the 
form of lack of efficacy with other antipsychotics 
could still exhibit improvement with paliperidone 
ER. At the same time, for patients who needed to 
switch antipsychotics for other reasons, such as 
lack of tolerability, the significant result is that the 
patients maintained their previous improvement as 
assessed by PANSS and CGI-S scores.
Unlike earlier post hoc analyses comparing 
outcomes in patients with recent-onset versus 
more-established disease [Canuso et  al. 2010; 
Macfadden et  al. 2010], the current study only 
included patients with recent-onset schizophrenia 
requiring an antipsychotic. As a result of the 
importance of treating schizophrenia early, future 
studies may wish to compare very long-term out-
comes among patients who had been treated 
when they still had more-recent-onset schizophre-
nia, and those with established disease who had 
started treatment later in the disease process.
In conclusion, flexibly dosed paliperidone ER 
treatment for up to 6 months was generally well 
tolerated, and associated with meaningful clinical 
response in non-acute patients recently diagnosed 
with schizophrenia who had been previously 
unsuccessfully treated with other oral antipsychot-
ics. Specifically, for patients switching for the main 
reason of lack of efficacy, more than half of patients 
achieved an improvement in PANSS total scores 
of at least 20% from baseline to endpoint, and for 
each reason for switching other than lack of effi-
cacy, maintenance of efficacy after switching to 
paliperidone ER was confirmed. Even more, 
patients who were switched for reasons other than 
lack of efficacy also demonstrated a statistically 
significant and meaningful improvement in clini-
cal symptoms.
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